These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18765198)

  • 21. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.
    John R; Pagani FD; Naka Y; Boyle A; Conte JV; Russell SD; Klodell CT; Milano CA; Rogers J; Farrar DJ; Frazier OH
    J Thorac Cardiovasc Surg; 2010 Jul; 140(1):174-81. PubMed ID: 20447659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.
    Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H
    Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alloimmunosensitization in left ventricular assist device recipients and impact on posttransplantation outcome.
    Urban M; Gazdic T; Slimackova E; Pirk J; Szarszoi O; Maly J; Netuka I
    ASAIO J; 2012; 58(6):554-61. PubMed ID: 23069898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
    Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
    Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion.
    Silveira FP; Marcos A; Kwak EJ; Husain S; Shapiro R; Thai N; McCurry KR; Abu-Elmagd K; Paterson DL
    J Infect; 2006 Oct; 53(4):241-7. PubMed ID: 16403576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection.
    Woodside KJ; Lick SD
    J Heart Lung Transplant; 2007 Jul; 26(7):750-2. PubMed ID: 17613409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Preparation of highly HLA-sensitized patient for heart transplantation: first documented case in Croatia].
    Gavranić BB; Basić-Jukić N; Ratković-Gusić I; Martinez N; Ivancan V; Kes P
    Acta Med Croatica; 2011; 65(4):301-4. PubMed ID: 22359900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasmapheresis during cardiopulmonary bypass: a proposed treatment for presensitized cardiac transplantation patients.
    Larson DF; Elkund DK; Arabia F; Copeland JG
    J Extra Corpor Technol; 1999 Dec; 31(4):177-83. PubMed ID: 10915474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
    Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
    Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In praise of ventricular assist devices-mechanical bridge to virtual crossmatch for the sensitized patient.
    Ross H; Tinckam K; Rao V; West LJ
    J Heart Lung Transplant; 2010 Jul; 29(7):728-30. PubMed ID: 20363155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allosensitization in bridge to transplant Novacor left ventricular assist device patients: analysis of long-term outcomes with regard to acute rejection and chronic allograft vasculopathy.
    Kirsch L; Timmermans T; Van Caenegem O; Gurne O; Noirhomme P; Jacquet LM; Latinne D; Poncelet AJ
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):268-74; discussion 274. PubMed ID: 18456505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
    Baez Y; Giron F; Niño-Murcia A; Rodríguez J; Salcedo S
    Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Campath induction for kidney transplantation: report of 297 cases.
    Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
    Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use.
    Das B; Shoemaker L; Recto M; Austin E; Dowling R
    J Heart Lung Transplant; 2008 Feb; 27(2):242-4. PubMed ID: 18267235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation?
    Kobashigawa JA; Sabad A; Drinkwater D; Cogert GA; Moriguchi JD; Kawata N; Hamilton MA; Hage A; Terasaki P; Laks H
    Circulation; 1996 Nov; 94(9 Suppl):II294-7. PubMed ID: 8901763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices.
    Kamdar F; John R; Eckman P; Colvin-Adams M; Shumway SJ; Liao K
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):575-81. PubMed ID: 23321132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart transplantation across antibodies against human leukocyte antigen and ABO-post-transplant follow-up of donor reactive antibodies.
    Bućin D; Johansson S; Lindberg LO
    Xenotransplantation; 2006 Mar; 13(2):101-4. PubMed ID: 16623800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation.
    Pisani BA; Mullen GM; Malinowska K; Lawless CE; Mendez J; Silver MA; Radvany R; Robinson JA
    J Heart Lung Transplant; 1999 Jul; 18(7):701-6. PubMed ID: 10452347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.